Clinical Trial Update: Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dacarbazine plus recombinant interferon alfa-2b in patients with primary uveal melanoma with genetic imbalance has completed; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma
• Intraocular Melanoma
• Uveal Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• recombinant interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Status: COMPLETED | Results posted: 2018-10-29